Functional Dyspepsia: Current Understanding and Future Perspective
Top Cited Papers
Open Access
- 18 August 2023
- journal article
- review article
- Published by S. Karger AG in Digestion
- Vol. 105 (1) , 26-33
Abstract
Background: Functional dyspepsia (FD) is a common disorder characterized by chronic or recurrent upper abdominal pain or discomfort without any structural abnormalities in the gastrointestinal tract. FD is categorized into two subgroups based on symptoms: postprandial distress syndrome (PDS) and epigastric pain syndrome. Summary: The pathophysiology of FD involves several mechanisms. Delayed gastric emptying is observed in approximately 30% of FD patients but does not correlate with symptom patterns or severity. Impaired gastric accommodation is important in the pathophysiology, particularly for PDS. Visceral hypersensitivity, characterized by heightened sensitivity to normal activities, contributes to the perception of discomfort or pain in FD. Alterations to the duodenal mucosa, including impaired mucosal barrier function and low-grade inflammation, are also implicated in the pathogenesis of FD. Microbial dysbiosis and psychological factors such as stress can further exacerbate symptoms. Treatment options include dietary modifications, establishing a physician-patient relationship, acid suppressants, prokinetics, neuromodulators, and behavioral therapies. Dietary recommendations include eating smaller, more frequent meals, and avoiding trigger foods. Acid suppressants are used as the first-line treatment. Prokinetics and neuromodulators aim to improve gastric motility and central pain processing, respectively. Behavioral therapies, including cognitive behavioral therapy and hypnotherapy, have shown benefits for refractory FD. Severe and refractory cases may require combination therapies or experimental treatments. Key Messages: FD is a disorder of gut-brain interaction involving diverse pathophysiological mechanisms. Individualized treatment based on symptoms and responses to interventions is crucial. Further research is needed to improve the understanding of FD and advance the development of effective therapies.Keywords
This publication has 67 references indexed in Scilit:
- Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsiaGut, 2013
- Generation of dyspeptic symptoms by direct acid and water infusion into the stomachs of functional dyspepsia patients and healthy subjectsAlimentary Pharmacology & Therapeutics, 2011
- Abuse History, Depression, and Somatization Are Associated With Gastric Sensitivity and Gastric Emptying in Functional DyspepsiaPsychosomatic Medicine, 2011
- Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosageNeurogastroenterology & Motility, 2010
- Clinical trial: a randomized controlled cross‐over study of flupenthixol + melitracen in functional dyspepsiaAlimentary Pharmacology & Therapeutics, 2008
- Non-ulcer Dyspepsia and Duodenal Eosinophilia: An Adult Endoscopic Population-Based Case-Control StudyClinical Gastroenterology and Hepatology, 2007
- Pathogenesis of irritable bowel syndrome: The mast cell connectionScandinavian Journal of Gastroenterology, 2005
- Pathophysiology of functional dyspepsiaBest Practice & Research Clinical Gastroenterology, 2004
- Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsiaGastroenterology, 1996
- Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluidNature, 1991